About the Company
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and a Union Army veteran of the American Civil War. As of 2022, Lilly is known for its clinical depression drugs Prozac (fluoxetine) (1986), Cymbalta (duloxetine) (2004), and its antipsychotic medication Zyprexa (olanzapine) (1996), although its primary revenue drivers are the diabetes drugs Humalog (insulin lispro) (1996) and Trulicity (dulaglutide) (2014). Lilly's achievements include being the first company to mass-produce the polio vaccine developed by Jonas Salk, and insulin. It was one of the first pharmaceutical companies to produce human insulin using recombinant DNA including Humulin (insulin medication), Humalog (insulin lispro), and the first approved biosimilar insulin product in the US, Basaglar (insulin glargine). As of 1997, it was the largest corporation and the largest charitable benefactor in Indiana. In 2009, Lilly pleaded guilty for illegally marketing Zyprexa and agreed to pay a $1.415 billion penalty that included a criminal fine of $515 million, the largest ever in a healthcare case and the largest criminal fine for an individual corporation ever imposed in a U.S. criminal prosecution of any kind at the time. As of 2019, the company was ranked 123rd on the Fortune 500. It is ranked 221st on the Forbes Global 2000 list of the largest public companies in the world and 252nd on the Forbes list of America's Best Employers. It is currently recognized as the top entry-level employer in Indianapolis. Lilly is a full member of the Pharmaceutical Research and Manufacturers of America and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LLY News
As Eli Lilly's Insulin Pricing Settlement Unravels, Lawyers Vow to Push Ahead
Lawyers touting a $500 million settlement over insulin pricing are back at the drawing board after a judge refused to certify ...
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight Loss Drug Market
Lilly recently announced news that could solve a big problem.
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With its 2-star rating, we believe Eli Lilly’s stock is overvalued compared with our long-term fair value estimate of $500.
Eli Lilly's nationwide insulin pricing settlement called off
A settlement between Eli Lilly and purchasers of its insulin drugs that would have capped prices and provided $13.5 million ...
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Pemvidutide is a glucagon-like peptide 1 (GLP-1) agonist which helps curb people's appetites, similar to how other popular ...
Zepbound and Mounjaro improve sleep apnea symptoms, Eli Lilly trial shows
A new clinical trial from drugmaker Eli Lilly shows that Zepbound and Mounjaro reduced obstructive sleep apnea symptoms.
As Zepbound shortage grows, Eli Lilly says no immediate end is in sight
The drugmaker is working to increase its supply of the weight loss drug. But some of those steps, including building a new ...
Eli Lilly and Company (LLY) Rose due to Robust Q4 Sales
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A ...
Loading the latest forecasts...